ADVERTISEMENT
Reviewing Benefits, Efficacy of Narcolepsy Treatment
Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, offers insight on the latest narcolepsy treatment in this 3-part podcast series.
Reviewing the Benefits of a New Therapy Option for Narcolepsy
Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, reviews research presented at the 2021 Sleep meeting, examining a new agent for narcolepsy called FT218, and explains how patients treated with this new option experienced statistically significant improvements in excessive daytime sleepiness and weekly cataplectic episodes. Listen here.
Investigational Narcolepsy Treatment Is Effective, Well-Tolerated Among Patients
Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, reviews a study presented at the 2021 Sleep meeting that examined the use of an investigational treatment, FT218, which significantly improved excessive daytime sleepiness and sleep quality among patients with narcolepsy, according to the study findings. Listen here.
Evaluating Efficacy of Narcolepsy Treatment for Patients Experiencing Various Sleep-Related Conditions
Michael Thorpy, MD, reviews a study presented at the 2021 Sleep meeting that evaluated the efficacy of the investigational, once-nightly controlled-release formulation of sodium oxybate, known as FT218, for the treatment of excessive daytime sleepiness, self-reported sleep quality/refreshing nature of sleep, sleep paralysis, and hypnagogic hallucinations among a cohort of patients with narcolepsy. Listen here.
